CompletedPHASE1, PHASE2NCT02128282
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Senhwa Biosciences, Inc.
- Principal Investigator
- Mitesh Borad, M.D.Mayo Clinic
- Intervention
- CX-4945(drug)
- Enrollment
- 127 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2021
Study locations (16)
- Mayo Clinic, Scottsdale, Arizona, United States
- University of Colorado- Denver, Aurora, Colorado, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
- Texas Oncology-Tyler, Tyler, Texas, United States
- Asan Medical Center, Seoul, Songpa-gu, South Korea
- Samsung Medical Center, Seoul, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Severance Hospital, Yonsei University Health System, Seoul, South Korea
- Chang-Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung City, Taiwan
- China Medical University Hospital, Taichung, Taiwan
- National Cheng Kung University Hospitals, Tainan, Taiwan
- National Taiwan University Hospital, Taipei, Taiwan
- Taipei Veterans General Hospital, Taipei, Taiwan
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02128282 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham